AN2728 is a boron-based small-molecule compound which reduces the production pro-inflammatory cytokines that are the precursors of the inflammation associated with psoriasis.
The double-blind, randomised, vehicle-controlled Phase 2b trial is designed to evaluate the safety and efficacy of AN2728 in patients with mild to moderate plaque-type psoriasis.
The trial has enrolled 68 patients with mild to moderate plaque-type psoriasis across ten centres in the US.
Patients have been randomised to 2% AN2728 topical ointment or vehicle in a 2:1 ratio and will apply the ointment twice daily for 12 weeks.
The trial is not designed to demonstrate statistical differentiation of AN2728 from vehicle, but to determine the size and design of the two planned pivotal Phase III trials for AN2728.